Technical Analysis for GNFT - GENFIT S.A.

Grade Last Price % Change Price Change
F 3.52 0.00% 0.00
GNFT closed unchanged on Monday, March 18, 2024, on 13 percent of normal volume.
Earnings due: Apr 4
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Gapped Down Weakness 1.15%
Lower Bollinger Band Touch Weakness 1.15%
NR7 Range Contraction -1.68%
Narrow Range Bar Range Contraction -1.68%
Gapped Up Strength -1.68%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 10 hours ago
Possible Inside Day about 10 hours ago
Possible NR7 3 days ago
Possible Inside Day 3 days ago
Down 5% 4 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GENFIT S.A. Description

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Alcohol Autoimmune Disease Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Hepatology Liver Disease Liver Diagnostic Solutions Primary Biliary Cholangitis Chronic Liver Disease Clinical Management

Is GNFT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.75
52 Week Low 2.8935
Average Volume 15,713
200-Day Moving Average 3.63
50-Day Moving Average 3.69
20-Day Moving Average 3.59
10-Day Moving Average 3.55
Average True Range 0.14
RSI (14) 44.75
ADX 9.28
+DI 16.89
-DI 24.89
Chandelier Exit (Long, 3 ATRs) 3.56
Chandelier Exit (Short, 3 ATRs) 3.82
Upper Bollinger Bands 3.75
Lower Bollinger Band 3.44
Percent B (%b) 0.26
BandWidth 8.52
MACD Line -0.05
MACD Signal Line -0.05
MACD Histogram -0.0073
Fundamentals Value
Market Cap 175.42 Million
Num Shares 49.8 Million
EPS -0.84
Price-to-Earnings (P/E) Ratio -4.19
Price-to-Sales 6.39
Price-to-Book 2.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.61
Resistance 3 (R3) 3.60 3.56 3.60
Resistance 2 (R2) 3.56 3.54 3.57 3.59
Resistance 1 (R1) 3.54 3.52 3.55 3.55 3.58
Pivot Point 3.50 3.50 3.51 3.51 3.50
Support 1 (S1) 3.48 3.48 3.49 3.49 3.46
Support 2 (S2) 3.44 3.46 3.45 3.45
Support 3 (S3) 3.42 3.44 3.45
Support 4 (S4) 3.43